Summary
No substantive, label-verifiable prescribing-information claims were provided by the AI response to compare against the supplied XELODA FDA label excerpts (DPD/DPYD testing/avoidance and vitamin K antagonist bleeding/INR monitoring). The response instead contains general market/generics and pharmacology statements that are not supported or contradicted by the provided label sections.
Category Scores
Accurate Statements
Unsupported Statements
Capecitabine is an oral chemotherapy medicine.
The provided FDA label excerpts do not establish that XELODA/capecitabine is an oral chemotherapy medicine.
Capecitabine is a prodrug that gets converted in the body into 5-fluorouracil.
The provided FDA label excerpts do not state prodrug conversion to 5-fluorouracil.
Generic capecitabine is sold by multiple companies under different brand names in different countries.
The provided FDA label excerpts do not discuss generic availability, marketing, or brand naming by country.
Generic capecitabine is typically sold after the originator product’s patent and market exclusivity periods end.
The provided FDA label excerpts do not discuss patent/exclusivity timing for generics.
Generic capecitabine is widely available in many markets.
The provided FDA label excerpts do not address market availability.
Generic manufacturers have entered as regulatory approval timelines and patent barriers allowed.
The provided FDA label excerpts do not discuss regulatory approval timelines or patent barriers for generics.
Generic capecitabine products are typically required to meet bioequivalence standards.
The provided FDA label excerpts do not mention bioequivalence requirements.
Bioequivalent generic capecitabine should deliver the active ingredient into the body at a similar rate and extent to the reference product.
The provided FDA label excerpts do not describe bioequivalence standards.
Differences between generic and reference capecitabine products in practice usually come from non-active ingredients (excipients) and tablet formulation, not the active drug itself.
The provided FDA label excerpts do not discuss generic/reference formulation differences or excipients.
Contradictions
Important Omissions
No statements addressing the supplied XELODA label excerpts: (1) DPYD/DPD deficiency testing and avoidance guidance, and (2) vitamin K antagonist (e.g., warfarin) bleeding risk with INR monitoring/dose adjustment.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The response does not provide dosing, contraindications, interaction management, or clinical safety instructions from the label; therefore it is not directly actionable from a label-adherence standpoint. However, it also does not include the key safety/monitoring information present in the supplied label excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Not Aligned
Primary Issue
No label-anchored prescribing-information claims were evaluated against the provided XELODA FDA label excerpts; most statements are unsupported by the supplied label text.
Suggested Improvement
Limit claims to what is explicitly supported by the provided XELODA label excerpts (DPYD/DPD testing/avoidance and vitamin K antagonist bleeding/INR monitoring). If other claims are needed, provide the corresponding label sections for evaluation.